We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > myeloid leukaemia

News List

FDA approves Pfizer’s Daurismo to treat acute myeloid leukaemia pharmaceutical-technology
November 25, 2018
The US Food and Drug Administration (FDA) has approved Pfizer’s Daurismo (glasdegib) indication to treat patients with newly diagnosed acute myeloid leukaemia (AML).
FDA approves Pfizer’s Daurismo to treat acute myeloid leukaemia pharmaceutical-technology
November 25, 2018
The US Food and Drug Administration (FDA) has approved Pfizer’s Daurismo (glasdegib) indication to treat patients with newly diagnosed acute myeloid leukaemia (AML).
Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3 pharmafile
August 02, 2018
It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) for the treatment of schizophrenia in adults, but its subsidiary’s investigational treatment guadecitabine failed to achieve
FDA approves new combination treatment for acute myeloid leukaemia europeanpharmaceuticalreview
May 05, 2017
The US Food and Drug Administration (FDA) has approved Novartis’ Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy